Please login to the form below

Not currently logged in
Email:
Password:

AZ's Faslodex recommended against in UK

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's breast cancer drug Faslodex not be used on the NHS

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's (AZ) breast cancer drug Faslodex (fulvestrant) not be used on the NHS.

The body, which regulates what treatments can be funded in England and Wales, claims that the drug does not represent a good use of NHS resources when used as an alternative to aromatase inhibitor therapy.

Faslodex is intended for use if anti-oestrogen treatments are no longer controlling the spread of the cancer in postmenopausal women who have locally advanced or metastatic breast cancer that is oestrogen-receptor-positive.

Commenting on the decision, Sir Andrew Dillon, chief executive of NICE, said: "After analysing the evidence comparing fulvestrant's clinical effectiveness with aromatase inhibitor therapy, our independent committee found that the estimates of overall survival and time to tumour progression were very uncertain."

There is now a consultation period until September 13, before a further review by an independent committee. Final guidance is expected in January 2012.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics